PPT-Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk

ProgressionFree Survival of Isa KRd in HighRisk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMGCONCEPT Trial Lisa B Leypoldt Diana Tichy Britta . Janice Love. University of California, Los Angeles. Office of Academic Planning & Budget. CAIR 2014. Agenda. Survival Analysis History . &. Background. Overview. Survival Analysis example using SPSS. Our Dana-Farber Experience. Deirdre Foley & Matthew Murphy. Our . Dana-Farber Experience. Dr O Gorman (. MIRT . Mater Institute of Blood Cancer Research and Therapy) and Dr Anderson (Dana Farber Cancer Institute, Boston). Dr Matthew Jenner. Consultant Haematologist. Southampton General Hospital . UK Myeloma Forum Autumn Day. 12 November 2014. Introduction. Why define high risk myeloma?. 3. Patient expectations. Outcomes vary widely between different patients. Presented by . N. ick Leghorn. Credentials. B.S., Security and Risk Analysis. The Pennsylvania State University. Risk Analyst for a government contractor. NSA Certified INFOSEC Professional. Speaker at The Last HOPE:. Diagnostic Criteria. Multiple Myeloma Requiring Therapy. Newly Diagnosed Multiple Myeloma. Primary Induction for SCT Candidates. Newly Diagnosed Multiple Myeloma. Maintenance Therapy. Newly Diagnosed Multiple Myeloma. new treatment in the horizon. Dr Amin . I. slam . MB, MRCP UK , FRCPath UK. Consultant haematologist and . H. aemato. -Oncologist. Southend University Hospital NHS Foundation trust. Myeloma patients support group meeting. Program Goals. Defining Multiple Myeloma. Case 1. Diagnostic Criteria. Multiple Myeloma Requiring Therapy. Cytogenetic Risk Features. Case 1 (cont). Newly Diagnosed Multiple Myeloma. NCCN. ®. . Therapy for Transplant-Eligible Patients. Copenhagen. , . June 11. th. . 2016. EU Drug Approval and Reimbursement Policy. No standardized. cost-benefit formula exists across the EU. . The Estonian reimbursement committee (Estonian Health Foundation) initially (2013) . Smoldering Myeloma: To Treat or not to Treat Ruben Niesvizky MD Myeloma Center Myelomacenter.org run9001@med.cornell.edu CASE A 47-year-old man is diagnosed with smoldering multiple myeloma . He has Part I: Smoldering Multiple Myeloma . and . Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma . Moderator: . Sagar. . Lonial. , MD. Panelists: . Jonathan Kaufman, MD and Ajay . Nooka. Although . genome profiling studies have demonstrated heterogeneity in subclonal architecture that may ultimately lead to relapse, a gene-expression based prediction program that can identify, distinguish and quantify drug response in subpopulations within a bulk population of myeloma cells is lacking. . Myeloma Symposium 9/29/2018. Aric Hall, MD – Assistant Professor – UW School of Medicine & Public Health. Disclosures. I have no significant conflicts of interest to disclose. . I have no financial relationship with any institution profiting from pharmaceutical sales, diagnostic testing, or any type of medical technology. . Risk stratification and Therapeutic Options. Natalie S. Callander, M.D.. University of Wisconsin Carbone Cancer Center. 1. MGUS definition. 2. Factors associated with MGUS progression. 3. Appropriate evaluation. Pragya Kumari. 1. , . Atanu. Bhattacharjee. 2. , Gajendra K. Vishwakarma. 1. 1. Indian Institute of Technology (ISM) Dhanbad, India, 826004. 2. Institute of . Acturial. . Sceience. and Data Analytics, UCSI University, Malaysia, 56000.